Targazyme

Targazyme

Founded 2008 11 employees Series A Total: $60.00M Biopharma, Biotechnology +2

Targazyme is a San Diego-based, clinical-stage biopharmaceutical company founded in 2008. The company focuses on developing novel enzyme-based platform technologies and products to enhance the clinical efficacy and cost of care outcomes for various medical areas including cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy, and regenerative medicine. Targazyme's clinical-grade fucosyltransferase enzymes and small molecule products (TZ101 and TZ102) are off-the-shelf biologic products used at the point-of-care to treat therapeutic cells immediately before infusion into the patient. The company has received worldwide patents, multiple FDA orphan drug designations, has an open investigational new drug application (IND) with multiple ongoing clinical studies, and a Phase 3 Special Protocol Assessment (SPA) with the FDA. Targazyme has received numerous medical and scientific awards and has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas M.D. Anderson Cancer Center, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California Los Angeles Medical Center, Stanford University Medical Center, University of Minnesota Medical Center, University of California San Diego Medical Center, Sanford-Burnham Medical Research Institute, Indiana University, Memorial Sloan Kettering Cancer Center, and New York Blood Center. The last investment in Targazyme was a $60.00M Series A investment by Kyowa Kirin and Texas Wide Open for Business on 15 July 2009. Learn more at http://www.targazyme.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	$60.00M	2	Kyowa Kirin, Texas Wide Open for Business	15 Jul 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

$60.00M

Kyowa Kirin, Texas Wide Open for Business

15 Jul 2009

FAQ About Targazyme

Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene...

Targazyme was founded in 2008.

Targazyme operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, enzyme-based therapies, cell therapy and immunotherapy.

Targazyme has approximately 11 employees.

Targazyme has completed 1 funding round, raising a total of $60.00M. The latest funding stage is Series A.

Top alternatives and competitors to Targazyme include SciTech Development, Inc., Arcellx, HRAIN BIOTECHNOLOGY, Imunopharm Technology, CEBIOTEX. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Targazyme and SciTech Development, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Targazyme

Funding Rounds & Investors (1)

Targazyme Alternatives & Competitors

FAQ About Targazyme